Literature DB >> 22104542

Factors influencing exercise performance in thoracic cancer.

Ruth England1, Matthew Maddocks, Cathann Manderson, Andrew Wilcock.   

Abstract

BACKGROUND: Patients with incurable thoracic cancer often complain of a reduced ability to exercise, but the cause of this has been little studied. Thus, we have explored how various physiological and psychological factors relate to exercise performance in this group.
METHODS: Inspiratory muscle strength, peripheral muscle power, lung function and mastery over breathlessness were assessed using sniff nasal inspiratory pressure, leg extensor power, simple spirometry and the mastery domain of the Chronic Respiratory Disease Questionnaire respectively. Exercise performance was assessed using the Incremental Shuttle Walking Test (ISWT) during which patients wore a K4 b(2) system permitting measurement of resting and breakpoint heart rate, minute ventilation (VE) and oxygen uptake (VO(2)). Relationships between ISWT distance and the four factors were determined using correlation and β regression coefficients.
RESULTS: Forty-one patients (21 male, mean (SD) age 64 (8) years) walked a median [IQR] of 320 [250-430] metres and reached a mean (SD) of 76 (10), 77 (25), and 48 (14) of their percent predicted maximum heart rate, VO(2), and VE respectively. Exercise performance was significantly associated only with inspiratory muscle strength (r = 0.42, P < 0.01) and peripheral muscle power (r = 0.39, P = 0.01). These factors were also significant determinants of exercise performance (β coefficients [95%CI] 1.77 [0.53, 3.01] and 1.22 [0.31, 2.14] respectively).
CONCLUSION: Of the factors examined, only inspiratory and peripheral muscle performance were significantly related to and predictive of exercise performance. Rehabilitation interventions which include inspiratory and peripheral muscle training are worth exploring further in this group of patients with thoracic cancer.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 22104542     DOI: 10.1016/j.rmed.2011.11.002

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  7 in total

1.  Diaphragm contractile dysfunction causes by off-target low-dose irradiation.

Authors:  Chen-Hsi Hsieh; Yun-Cheng Lin; Yu-Jen Chen; Huey-Dong Wu; Li-Ying Wang
Journal:  Am J Transl Res       Date:  2016-03-15       Impact factor: 4.060

2.  Exercise for cancer cachexia in adults.

Authors:  Antonio Jose Grande; Valter Silva; Larissa Sawaris Neto; João Pedro Teixeira Basmage; Maria S Peccin; Matthew Maddocks
Journal:  Cochrane Database Syst Rev       Date:  2021-03-18

3.  Sniff nasal inspiratory pressure does not decrease in elderly subjects.

Authors:  Chien-Hui Huang; Gee-Gwo Yang; Tung-Wei Chen
Journal:  J Phys Ther Sci       Date:  2014-09-17

Review 4.  Efficacy of Anamorelin, a Novel Non-Peptide Ghrelin Analogue, in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) and Cachexia-Review and Expert Opinion.

Authors:  David C Currow; Matthew Maddocks; David Cella; Maurizio Muscaritoli
Journal:  Int J Mol Sci       Date:  2018-11-05       Impact factor: 5.923

Review 5.  Functional capacity, physical activity and muscle strength assessment of individuals with non-small cell lung cancer: a systematic review of instruments and their measurement properties.

Authors:  Catherine L Granger; Christine F McDonald; Selina M Parry; Cristino C Oliveira; Linda Denehy
Journal:  BMC Cancer       Date:  2013-03-20       Impact factor: 4.430

6.  Which field walking test should be used to assess functional exercise capacity in lung cancer? An observational study.

Authors:  Catherine L Granger; Linda Denehy; Selina M Parry; Joel Martin; Tim Dimitriadis; Maeve Sorohan; Louis Irving
Journal:  BMC Pulm Med       Date:  2015-08-12       Impact factor: 3.317

Review 7.  Exercise for cancer cachexia in adults: Executive summary of a Cochrane Collaboration systematic review.

Authors:  Antonio Jose Grande; Valter Silva; Matthew Maddocks
Journal:  J Cachexia Sarcopenia Muscle       Date:  2015-07-07       Impact factor: 12.910

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.